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Abstract
Background: Skeletal muscle atrophy is a serious concern for the rehabilitation of patients afflicted by prolonged
limb restriction. This debilitating condition is associated with a marked activation of NFB activity. The ubiquitin-
proteasome pathway degrades the NFB inhibitor IBa, enabling NFB to translocate to the nucleus and bind to
the target genes that promote muscle atrophy. Although several studies showed that proteasome inhibitors are
efficient to reduce atrophy, no studies have demonstrated the ability of these inhibitors to preserve muscle
function under catabolic condition.
Methods: We recently developed a new hindlimb immobilization procedure that induces significant skeletal
muscle atrophy and used it to show that an inflammatory process characterized by the up-regulation of TNFa,a
known activator of the canonical NFB pathway, is associated with the atrophy. Here, we used this model to
investigate the effect of in vivo proteasome inhibition on the muscle integrity by histological approach. TNFa, IL-1,
IL-6, MuRF-1 and Atrogin/MAFbx mRNA level were determined by qPCR. Also, a functional measurement of
locomotors activity was performed to determine if the treatment can shorten the rehabilitation period following
immobilization.
Results: In the present study, we showed that the proteasome inhibitor MG132 significantly inhibited IBa
degradation thus preventing NFB activation in vitro. MG132 preserved muscle and myofiber cross-sectional area
by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA in vivo. This effect
resulted in a diminished rehabilitation period.
Conclusion: These finding demonstrate that proteasome inhibitors show potential for the development of
pharmacological therapies to prevent muscle atrophy and thus favor muscle rehabilitation.
Background
Skeletal muscle atrophy may be caused by prolonged
immobilization, which has a significant impact on the
duration and intensity of rehabilitation [1]. It is charac-
terized by increased muscle fatigability associated with
changes in muscle fiber size, reduced muscle protein
synthesis [2], and enhanced muscle protein ubiquitina-
tion and degradation [3,4]. The pro-inflammatory cyto-
kine TNFa has been reported to be involved in the
process of muscle wasting by causing myofibrillar pro-
tein degradation via the ubiquitin proteasome pathway
[5]. By activating transcription factor NFB, TNFa plays
a central role in regulating muscle protein catabolism in
vitro and in vivo [6-8]. Mourkioti et al. have shown that
muscle genetically depleted of NFB exhibits increased
strength, diminished protein degradation under atrophic
conditions, and enhanced regeneration in response to
injury [9]. Moreover, it has recently been reported that
muscle atrophy caused by NFB activation is associated
with the induction of MuRF-1 [8,10] and Atrogin/
MAFbx [11], two markers of atrophy [12,13]. Interest-
ingly, we recently showed that immobilization induced-
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inflammatory cytokines TNFa, IL-1, and IL-6 concomi-
tantly with an up-regulation of MuRF-1 and Atrogin/
MAFbx [14]. The idea that inflammation may play a sig-
nificant role in inducing skeletal muscle atrophy has also
been proposed by Hirose et al. [15] and Andrianjafini-
ony et al. [16].
Inactive NFB is retained in the cytoplasm through its
association with IBa. However, when stimulated with
pro-inflammatory cytokines (TNFa,I L - 1 ,I L - 6 ) ,I Ba is
phosphorylated, ubiquitinated, and degraded through
the proteasome machinery, allowing free NFB to trans-
locate to the nucleus to transactivate its target genes
[17]. The inhibition of the proteasome machinery pre-
vents the degradation of IBa,w h i c hm a i n t a i n sN F B
in its inactive state [18], thus preventing the up-regula-
tion of MuRF-1 and Atrogin/MAFbx. The present study
suggested that the NFB canonical pathway plays a cen-
tral role in immobilization-induced skeletal muscle atro-
phy and that proteasome inhibitors prevent muscle
atrophy by maintaining NFB in an inactive state.
Interestingly, proteasome machinery inhibitors reduce
skeletal muscle proteolysis in vitro [19-21]. Proteasome
inhibitors (Velcade™ and MG132) also prevented mus-
cle mass loss in an in vivo rat model of skeletal muscle
wasting induced by denervation and cast immobilization
of the hindlimb [22,23]. However, it is unclear whether
the prevention of muscle mass loss by proteasome inhi-
bitors can lead to functional.
To explore the effect of proteasome inhibitors on pre-
venting muscle atrophy following hindlimb immobiliza-
tion, we investigated the mechanism by which the
proteasome inhibitor MG132 affects the NFB canonical
pathway in the C2C12 myogenic cell line. We also
explored the effect of MG132 in an in vivo mouse
model of skeletal muscle wasting induced by immobili-
zation in which the tibialis anterior (TA) muscle under-
goes rapid atrophy. Time to exhaustion experiments
showed that proteasome inhibition markedly accelerates
the rate of rehabilitation following immobilization. In
summary, the effect of MG132 indicated that protea-
some inhibitors show promise as pharmacological agents
for preventing muscle atrophy and for favoring the reha-
bilitation of patients following severe trauma or surgery.
Methods
Animals and muscle atrophy-induced procedure
Sixteen-week-old male CD1 mice (Charles River, Mon-
treal, QC, Canada) were used for all our experiments.
Thirty minutes before the immobilization procedure, 0.1
mg/kg of buprenorphine was administrated IP. The
mice were then anesthetized using isoflurane. The right
hindlimb was immobilized as previously described [14].
Briefly, the hindlimb was immobilized 7 days by stapling
the foot exploiting normal dorso-tibial flexion using an
Autosuture Royal 35W skin stapler (Tyco Healthcare,
Pointe Claire, QC, Canada). One tine was inserted close
to the toe at the plantar portion of the foot while the
other was inserted in the distal portion of the gastrocne-
mius. The other hindlimb was used as a control. During
the immobilization period, the mice were injected sub-
cutaneously with MG132 (7.5 mg/kg/dose) or vehicle
(DMSO) twice daily. DMSO containing or not MG132
was diluted in sterile pure corn oil (1:100, injected
volume 150 μL). After 7 days, the tibialis anterior (TA)
muscles of immobilized and non-immobilized hindlimbs
from MG132- and DMSO-treated mice were either har-
vested or unstapled for remobilization studies. MG132
or DMSO was given only during the immobilization
period.
Cast immobilization was performed according to an
adapted procedure described by Frimel et al. [24].
Briefly, hindlimbs were immobilized in the neutral posi-
tion (160-180°). The ankle was fixed at 90° to keep the
TA resting. The plaster of Paris cast encompassed both
hindlimbs as in a hip spica. A thin layer of padding was
placed underneath the cast in order to prevent abra-
sions. With the ankles at a straight angle, the cast did
not have to be tight to prevent the mice from getting
out of the cast. Care was taken to minimize the weight
of the cast.
All animal experiments were approved by the Animal
Ethics Committee of Université de Sherbrooke and were
performed in accordance with Canadian Council on
Animal Care guidelines (protocol #133-06B).
Cell culture and treatment
C2C12 cells were cultured in complete proliferation
medium consisting of DMEM supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 IU/ml of
penicillin, and 100 μg/ml of streptomycin. Differentia-
tion was initiated by replacing the cell growth medium
with differentiation medium (DMEM supplemented with
5% horse serum and antibiotics). After 96 h, the C2C12
cells had differentiated into myotubes and were treated
with 40 μM MG132 in DMSO or vehicle (DMSO). After
a 1-h treatment, the cells were stimulated or not with
TNFa (50 ng/ml) in presence or absence of MG132.
Measurement of NFB transcriptional activity
C2C12 cells were cultured in six-well tissue culture
plates (3 × 10
5 cells/well) and transiently co-trans-
fected with an NFB-luciferase reporter plasmid
(pNFB-luc, 1 μg, a generous gift from Dr. T. E Gun-
ter, University of Rochester, NY, USA) and a control
Renilla luciferase plasmid (pRL-CMV, 30 ng, Promega,
Madison WI, USA) in Lipofectamine 2000 transfection
reagent (Invitrogen, Burlington, ON, Canada). Twenty-
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was replaced by differentiation medium, and the incu-
bation was continued for an additional 96 h. Differen-
tiated cells were then treated with MG132 (40 μM) or
vehicle (DMSO). After a 1-h treatment, the cells were
stimulated or not with TNFa (50 ng/ml). Six hours
later, the cells were washed twice with PBS and lysed
to determine transcriptional activity using a reporter
assay system (Promega, Madison, WI, USA) and a SIR-
IUS luminometer (Berthold Detection Systems, Pforz-
hein, Germany).
Electrophoresis and immunoblotting
Protein extracts from C2C12 myotubes were solubilized
in RIPA buffer (0.5% NP-40, 0.1% sodium deoxycholate,
150 mM NaCl, 50 mM Tris-HCl, pH 7.5) supplemented
with Complete™ Protease Inhibitor Cocktail (Roche
Molecular Biochemicals, Laval, QC, Canada). The
homogenates were centrifuged at 14,000 rpm for 10 min
at 4°C and the supernatants were collected. The protein
concentrations in the supernatants were measured using
Bradford’s method (BioRad). The protein extracts (50
μg) were separated on a 12% polyacrylamide gel and
electrotransferred to a polyvinylidene fluoride membrane
(PVDF) (Millipore, Bedford, MA, USA). Blotted mem-
branes were incubated overnight at 4°C in PBS-T (8
mM NaH2PO4, 1.5 mM KH2PO4, 3.5 mM KCl, 137 mM
NaCl) containing 0.1% Tween-20 with anti-IBa
(1:1,500) or anti-GAPDH antibody (1:1,000) (Santa Cruz
Biotechnology, Santa-Cruz, CA, USA). After extensive
washing with PBS-T, the blots were incubated for 1 h at
room temperature with a peroxidase-conjugated second-
ary antibody. After extensive washing with PBS-T, the
immunostained bands were revealed with ECL Plus
according to the manufacturer’s instructions on a Bio-
Max ML film (Kodak, Rochester, NY, USA). The autora-
diograms were digitized and the bands were quantified
by densitometric measurements using ImageJ software
[25].
Quantitative PCR
Total RNA was extracted from flash-frozen crushed
TA muscle and C2C12 myotubes using TRIzol
®
reagent according to the manufacturer’si n s t r u c t i o n s .
The RNA was reverse-transcribed using Reverse Tran-
scriptase Superscript II. qPCR assays were performed
using 50 ng of template cDNA. The conditions for all
the reactions were as follows: an initial 5 min dena-
turation step at 95°C, followed by forty 40-s cycles at
95°C, 56°C, and 72°C. The qPCR assays were per-
formed using a Rotor-Gene 6000 (Corbett Robotics,
Australia) and iQSYBR Green Supermix (BioRad).
Results were calculated using the 2
-ΔΔCT relative quan-
tification method normalized to the HPRT1 gene. The
primer sets are shown in Table 1.
Histology
TA muscles were excised, fixed in formalin, and
embedded in paraffin. Sections (5 μm) were stained with
hematoxylin and eosin (H&E). The H&E-stained sec-
tions were used for the cross-sectional area (CSA) ana-
lyses. Over 40 myofibers/field from at least six different
fields were examined (20× magnification) using an opti-
cal microscope (TE-2000-S; Nikon, Mississauga, ON,
Canada) and the myofiber cross-sectional areas were
measured using ImageJ software [25].
Functional measurement of locomotor ability - Running
time
The locomotor ability (running time) of mice that had
both hindlimbs immobilized for 7 days before the sta-
ples were removed was measured using a treadmill
(Panlab/Harvard Apparatus, Barcelona, Spain). The mice
were divided into groups of 9-10 animals each. The
groups received either twice-daily subcutaneous injec-
tions of MG132 in canola oil (7.5 mg/kg/dose) or vehi-
cle (DMSO in canola oil) immediately after the
immobilization procedure and then for the duration of
the 7-day immobilization period. We compared the two
groups to a group of non-hindlimb-immobilized age-
matched mice. The running time experiment was per-
formed using a two-lane motorized treadmill equipped
with shocker plates. The treadmill was run at an inclina-
tion of +25° at 8 m/min for 5 min, after which the speed
was increased to 10 m/min for 2 min and then 20 m/
min. The test was stopped when the mouse remained
on the shocker plate for more than 15 s without
Table 1 Primer sets used for quantitative PCR analyses
Gene NCBI Accession Number Forward Primer Reverse Primer Product Size (bp)
Hprt1 NM_013556.2 5’- gcaaactttgctttccctgg -3’ 5’- acttcgagaggtccttttcacc -3’ 85
MuRF-1 DQ229108 5’-tgcctggagatgtttaccaagc-3’ 5’-aaacgacctccagacatggaca-3’ 143
Atrogin-1/MAFbx AF441120 5’-aaggctgttggagctgatagca-3’ 5’-cacccacatgttaatgttgccc-3’ 223
Il-1b NM_008361 5’-gcccatcctctgtgactcat-3’ 5’-aggccacaggtattttgtcg-3’ 230
Il-6 NM_031168 5’-agttgccttcttgggactga-3’ 5’-tccacgatttcccagagaac-3’ 159
TNFa NM_013693 5’-ccgatgggttgtaccttgtc-3’ 5’-tggaagactcctcccaggta-3’ 217
qPCR conditions for all reactions included an initial 5 min denaturation step at 95°C, followed by forty 40-s cycles at 95°C, 56°C, and 72°C.
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was determined from the beginning of the test. The run-
ning time experiments were performed 4 and 11 days
after removing the staples and on days 0 and 7 for the
non-hindlimb-immobilized age-matched control mice.
Statistics
All data are expressed as means ± SEM. Paired t-tests
were used to assess the statistical significance of differ-
ences between treated muscles and untreated contralat-
eral muscles. Unpaired t-tests were used to compare
two groups of mice or two different time points. A p <
0.05 was considered statistically significant. Statistical
values were calculated using GraphPad Prism 5.0
software™.
Results
MG132 inhibited TNFa-induced proteasome activation in
differentiated C2C12 cells
In a previous study, we showed that immobilization-
induced skeletal muscle atrophy is associated with the
upregulation of the inflammation markers TNFa,I L - 6 ,
and IL-1 [14]. The stimulation of TNFa, a well-known
activator of the NFB canonical pathway, causes the
rapid degradation of IBa through proteasome activa-
tion, resulting in the release of NFB, which translocates
to the nucleus where it binds to the target genes that
promote muscle atrophy [26].
Since the inhibition of the proteasome can prevent
IBa degradation and NFB translocation to the
nucleus of many cell types [27,28], we first investigated
whether this was the case for myotubes from the differ-
entiated mouse myogenic cell line C2C12. We measured
IBa protein levels by Western blot analysis in termin-
ally differentiated C2C12 cells exposed to TNFa in the
absence or presence of the proteasome inhibitor
MG132. In the presence of TNFa, the amount of IBa
was significantly lower after 30 min in terminally differ-
entiated C2C12 cells (35 ± 7%) compared to TNFa-trea-
ted cells exposed to MG132 (Figure 1). After 120
minutes, the amount of IBa protein was greater than
after 30 min and had almost returned the initial basal
level (Figures 1A and 1B). A densitometry analysis
clearly indicated that IBa was rapidly degraded after
30 min but rebounded after 120 min of TNFa stimula-
tion (Figure 1B). These results can be consistent with
the previously reported de novo synthesis of IBa[18].
We used an NFB-dependent luciferase reporter assay
to confirm that MG132 suppressed NFB activity by
inhibiting the proteasomal degradation of IBa. C2C12
myoblasts transfected with the NFB-luciferase reporter
gene were terminally differentiated for 5 days before
TNFa (50 ng/ml) was added in the absence or presence
of MG132 (40 μM). Six hours of stimulation with TNFa
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Figure 1 MG132 inhibited TNFa-induced proteasome activation
in differentiated C2C12 cells. (A) Western blot showing IBa
expression in differentiated C2C12 pre-treated with vehicle (DMSO)
or MG132 for 1 h followed by stimulation with TNFa (50 ng/ml) for
5, 10, 15, 30, and 120 min in presence or absence of MG132.
GAPDH was used as a loading control. (B) Graphical representation
of IBa expression levels over time indicating that a pre-treatment
with MG132 (dashed line) was able to prevent IBa degradation
compared to cells pre-treated with the vehicle (DMSO) (solid line).
(C) C2C12 myoblasts co-transfected with the NFB-luciferase and
Renilla luciferase reporter vectors. They were then differentiated and
stimulated with TNFa for 6 h in the presence or absence of MG132.
The ratio of Luciferase:Renilla activities indicates that the presence of
MG132 prevented the binding of NFB to the luciferase promoter.
(D) Graphs showing MuRF-1 and Atrogin/MAFbx qPCR expression
data from C2C12 myotubes stimulated or not with TNFa (50 ng/ml)
for 1 h. TNFa caused the expression of the muscle-specific ubiquitin
ligases MuRF-1 and Atrogin/MAFBx. (E) To evaluate the impact of
MG132 on MuRF-1 and Atrogin/MAFbx expression, differentiated
C2C12 were pre-treated or not with MG132 (40 μM) for 1 h before
being stimulated with TNFa (50 ng/ml) for 1 h. Expression of MuRF-
1 and atrogin/MAFbx was quantified by qPCR. MG132 inhibited the
expression of MuRF-1 and atrogin/MAFbx. Data are presented as the
means ± SEM of at least four independent experiments performed
in triplicate. (*p < 0.05, **p < 0.005, ***p < 0.001 compared to
control).
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activity in control cells compared to cells treated with
MG132 (Figure 1C), indicating that the inhibition of the
proteasome by MG132 was sufficient to inhibit the
degradation of IBa and thus reduce the transcriptional
activity of NFB in terminally differentiated C2C12 cells.
The exposure of muscle to an inflammatory milieu is
known to accelerate protein degradation that may occur
via the ubiquitin proteasome pathway [29-32]. We thus
determined whether TNFa can induce atrophy in term-
inally differentiated C2C12 cells by measuring the
expression of the muscle-specific ubiquitin ligases atro-
gin-1/MAFbx-1 and MuRF-1 genes, two molecular mar-
kers of atrophy. There was a significant induction of
MuRF-1 (1.9 ± 0.2 fold) and atrogin-1/MAFbx-1 mRNA
(2.2 ± 0.1 fold) in cells stimulated with TNFa for 1 h
compared to unstimulated cells (Figure 1D). To investi-
gate the impact of MG132 on the expression of MuRF-1
and atrogin-1/MAFbx-1 mRNA, cells were treated with
MG132 for 1 h prior to being stimulated for 1 h with
TNFa. MG132 dramatically decreased the induction of
both MuRF-1 (0.08 ± 0.001) and atrogin-1/MAFbx-1
(0.16 ± 0.006) in the presence of TNFa (Figure 1E), sug-
gesting that TNFa promotes atrophy via a proteasome-
dependent pathway.
Our results also revealed that the stimulation of TNFa
led to the activation of the NFB canonical pathway in
the differentiated myogenic cell line C2C12. This
inflammatory stimulus can induce the up-regulation of
both MuRF-1 and Atrogin/MAFbx, which are responsi-
ble for muscle protein loss during atrophy. Interestingly,
MG132 inactivated NFB and, concomitantly, the
expression of MuRF-1 and atrogin-1/MAFbx-1.
MG132 inhibited the key pathways involved in muscle
atrophy
In a previous study, we described an original immobili-
zation procedure for inducing skeletal muscle atrophy.
The atrophy was associated with the presence of inflam-
mation and the up-regulation of muscle-specific ubiqui-
tin ligases [14]. Since MG132 was able to down-regulate
t h ee x p r e s s i o no fM u R F - 1a n da t r o g i n - 1 / M A F b x - 1i n
terminally differentiated C2C12 cells, we next evaluated
the in vivo effect of MG132 on the expression of these
ligases in our immobilization-induced skeletal muscle
atrophy model. TA muscles from mice in which one
hindlimb was immobilized for 7 days while the contral-
ateral was not. The mice were injected subcutaneously
with MG132 or DMSO (vehicle) for 7 days of immobili-
zation and the TA muscles were then harvested. There
was no significant difference between the total mean
body weights of the MG132- and DMSO-treated mice
after 7 days of immobilization using staples (Figure 2A).
qPCR analyses revealed a robust and significant increase
in the expression of TNFa, IL-6, and IL-1 (2.79 ± 0.55,
5.39 ± 0.59, and 9.48 ± 3.05 fold, respectively) in the
immobilized TA muscle compared to contralateral TA
muscle of vehicle-treated mice (Figure 2B). Interestingly,
the atrophy caused by a plaster cast (see additional file
1A-B), also revealed a significant increase in the same
inflammatory factors within the TA muscles 24 h, 3.5 d,
and 7 d post-immobilization (see additional file 1C),
which was concomitant with the expression of the mus-
cle-specific ubiquitin ligases (see additional file 1D). It
should be noted that the expression of the inflammatory
molecules was not due to the presence of the staple or
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Figure 2 MG132 inhibited the key pathways involved in
muscle atrophy. (A) Histogram showing the body weights of
MG132- and DMSO-treated mice at day 0 (n = 8) and day 7 (n = 8)
of immobilization using staples. As can be seen, there was no
difference in total mean body weight between the MG132- and
DMSO-treated mice. (B) TNFa, IL-6, and IL-1 mRNA levels were
measured by qPCR. Data show a robust expression of TNFa, IL-6,
and IL-1 in the immobilized hindlimb compared to the non-
immobilized contralateral hindlimb of the DMSO-treated mice.
Immobilization-induced mRNA expression was totally inhibited in
the MG132-treated mice (n = 8 mice/condition). (C) qPCR
expression analyses showing that MG132 was able to prevent the
up-regulation of MuRF-1 and Atrogin/MAFbx in immobilized
hindlimbs compared to DMSO-treated mice (n = 8 mice/condition).
Data are presented as means ± SEM. (*p < 0.05, **p < 0.005, ***p <
0.001 compared to control).
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Page 5 of 11the dorso-tibial flexion position of the foot, which sug-
gests that inflammation observed in the staple model
was due to the immobilization. However, there were no
significant differences in TNFa,I L - 6 ,a n dI L - 1m R N A
levels in the immobilized and non-immobilized contral-
ateral TA muscles from the MG132-treated mice, indi-
cating that MG132 was able to inhibit the expression of
inflammation markers known to be regulated by the
NFB canonical pathway.
The ability of our hindlimb immobilization model to
induce skeletal muscle atrophy is related to the increase
in MuRF-1 and atrogin-1/MAFbx-1 levels (1.34 ± 0.17-
and 6.64 ± 0.39-fold, respectively) (Figure 2C). No sig-
nificant difference was observed between MuRF-1
mRNA levels in immobilized and non-immobilized con-
tralateral TA muscles from MG132-treated mice. How-
ever, the MG132 treatment significantly reduced the
mRNA expression of atrogin-1/MAFbx-1 as compared
to the control (DMSO-treated) immobilized TA mus-
cles. Together these results suggest that MG132 can
prevent the onset of the inflammatory process and can
also contribute to the down-regulation of MuRF-1 and
atrogin-1/MAFbx-1, two critical modulators of muscle
atrophy.
Immobilization-induced atrophy was prevented by
MG132
Skeletal muscle atrophy is characterized by a reduction
in skeletal muscle mass and myofiber diameter, two fea-
tures that are readily evident following hindlimb immo-
bilization [14]. Since MG132 significantly reduced
muscle ubiquitin ligase levels, thus causing myofibrillar
degradation, we investigated the effect of MG132 on the
TA muscles of immobilized and non-immobilized con-
tralateral hindlimbs. After 7 days of immobilization, we
observed an increase in the percentage of weight loss
(11.1 ± 1.8%) calculated from the contralateral TA mus-
cles in DMSO-treated mice (Figure 3A). Interestingly,
the MG132 treatment significantly reduced the percen-
tage of weight loss (atrophy) in TA muscles from immo-
bilized hindlimbs, with a loss of muscle wet mass of
only 3.04 ± 1.3% in MG132-treated mice, or 3.6-fold
less than in DMSO-treated mice (Figure 3A).
To better characterize the effect of MG132 on muscle
mass wasting, we performed histological analyses of TA
muscles. H&E staining of TA muscle paraffin cross-sec-
tions revealed that immobilization induced significant
atrophy in DMSO-treated mice as shown by the consid-
erable reduction in myofiber CSA. As expected, the
myofiber CSA of TA muscles from MG132-treated mice
appeared to be the same for both immobilized hin-
dlimbs and non-immobilized contralateral hindlimbs
(Figure 3B). Image analyses showed that the CSA of
myofibers of TA muscles from DMSO-treated mice had
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Figure 3 Immobilization-induced atrophy was prevented by
MG132. (A) Graph showing the percentage of atrophy of tibialis
anterior (TA) muscles from the hindlimbs of MG132- and vehicle
(DMSO)-treated mice after 7 days of immobilization. The percentage
of TA atrophy was calculated by comparing each immobilized TA
muscle to the respective non-immobilized contralateral TA muscle
such that each animal served as its own control (n = 16). MG132
significantly attenuated the loss of muscle mass due to
immobilization at day 7 post-immobilization. (B) H&E-stained cross-
sections of immobilized and non-immobilized contralateral TA
muscles from MG132- and vehicle (DMSO)-treated mice. The results
show that MG132 prevented myofiber atrophy in the TA muscles.
(C) Histogram showing the percentage area of myofiber (CSA) of TA
muscles from immobilized and non-immobilized contralateral TA
muscles isolated from MG132- (non-immobilized contralateral, n =
536 myofibers; immobilized, n = 643 myofibers) and DMSO-treated
mice (non-immobilized contralateral, n = 241 myofibers;
immobilized n = 302 myofibers). MG132 maintained the fiber size of
immobilized TA muscles. Data are presented as means ± SEM. For
the CSA of muscle myofibers, data are expressed as means ± SEM.
(*p < 0.05, **p < 0.005, ***p < 0.001 compared to control)
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Page 6 of 11decreased to 82.5 ± 2.1% compared to 96.2 ± 2.1% to
the CSA of myofibers of TA muscles from MG132-trea-
ted mice (Figure 3C). These measurements were
obtained by comparing the CSA of immobilized TA
muscles to CSA of non-immobilized contralateral TA
muscles, which was arbitrary fixed at 100%. In addition,
histological analyses revealed that there were no signifi-
cant compound-related adverse effects in skeletal muscle
from MG132-treated mice (Figure 3B).
These results indicate that MG132 was able to prevent
immobilization-induced skeletal muscle atrophy as
shown by the preservation of muscle mass and the
maintenance of myofiber size.
MG132 diminished the recovery time of muscle following
hindlimb immobilization
I nap r e v i o u ss t u d y ,w es h o w e dt h a tr u n n i n gp e r f o r -
mance was lower following hindlimb immobilization
and that this could be reversed during the remobiliza-
tion period [14]. Since MG132 prevented skeletal muscle
atrophy following hindlimb immobilization, we investi-
gated whether MG132 had an impact on muscle
strength and locomotor ability per se. We performed a
running time experiment with mice that had both hin-
dlimbs immobilized. The mice were separated into two
groups. The first group was treated with vehicle
(DMSO) and the second, with MG132. After 7 days of
immobilization, the staples were removed, and the hin-
dlimbs were remobilized after which functional recovery
was assessed (Figure 4A). After 4 days of remobilization,
the DMSO-treated mice had a significantly shorter run-
ning time (27.6 ± 14.8 min) than the MG132-treated
mice (76.6 ± 13.4 min) (Figure 4A). After 11 days of
remobilization, there was no significant difference in the
running time of DMSO- and MG132-treated mice (83.8
± 18.2 min and 115.4 ± 3 min, respectively) (Figure 4A).
Interestingly, there was no significant difference in the
running time of the MG132-treated mice after 4 and 11
days of remobilization (76.6 ± 13.4 versus 115.4 ± 3
min), whereas it took 11 days for the DMSO-treated
mice to completely recover, suggesting that MG132
reduced the effect of immobilization-induced atrophy,
which was reflected by the longer running time of
MG132-treated mice than of DMSO-treated mice after
4 days of remobilization. The body weights remained
stable for 11 days following remobilization (Figure 4B).
To verify whether the running time values of the mice
following remobilization were optimal, we added a con-
trol group of mice that had never had their hindlimbs
immobilized. The running time of the control group
was not significantly different from that of mice that
had been remobilized for 11 days, indicating that the
mice had completely recovered from the 7-day immobi-
lization after 11 days of remobilization.
Figure 4 MG132 diminished the recovery time of muscle
following hindlimb immobilization. (A) The mice were
immobilized using surgical staples (both hindlimbs) with or without
the MG132 treatment. After 7 days, the staples were removed and
the mice were remobilized. Running time experiments were
performed using the treadmill. Histogram showing that the MG132-
treated mice (n = 10) displayed a longer physical performance on
day 4 post-remobilization compared to the DMSO-treated mice (n =
10). However, there was no significant difference on day 11 post-
remobilization (n = 9-10 mice/condition). In addition, there was no
significant difference, after a 7 day remobilization period, with the
physical performance of age-matched control mice (gray column)
that had never been immobilized, indicating that training did not
improve the physical performance (n = 5). Data are presented as
means ± SEM. (*p < 0.05, **p < 0.005, ***p < 0.001 compared to
control). (B) Histogram showing the body weights of the same
MG132- and DMSO-treated mice after 4 (n = 8) and 11 (n = 8) days
of remobilization. As can be seen, there was no difference in total
mean body weight between the MG132- and DMSO-treated mice.
(C) Photographs showing the ventral part of the foot in which the
staple had been inserted. A slight insult was observed 1 day after
the staple was removed (1 day of remobilization). After 4 days of
remobilization, which corresponded to a time point in the treadmill
performance experiment, the insult had completely disappeared.
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tion procedure had little impact on the ventral side of
the foot. A slight insult was observed 1 day after staple
was removed (1 day of remobilization) and had comple-
tely disappeared after 4 days of remobilization, indicat-
ing that the immobilization p r o c e d u r el i k e l yd i dn o t
change the capacity of the mice to perform the running
time experiment on the treadmill (Figure 4C).
Discussion
Skeletal muscle atrophy caused by immobilization is a
major challenge for patient rehabilitation. The develop-
ment of therapies designed to prevent or attenuate ske-
letal muscle atrophy will fill an important medical need.
Many therapeutic trials focusing on the TNFa-NFB
pathway have been undertaken with the purpose of
reducing the impacts of muscle diseases. For example,
anti-TNFa antibodies (Remicade™) have been show to
interfere with TNFa activity and consequently reduce
the breakdown of dystrophic muscles [33]. A systemic
treatment with curcumin, an NFB inhibitor, has been
shown to stimulate muscle regeneration after traumatic
injury [34]. The use of a synthetic double-stranded oli-
godeoxynucleotide as a cis-element to block the binding
of NFB to promoter regions has been shown to inhibit
cachexia in a mouse tumor model [35]. Another strategy
to interfere with the NFB signaling pathway involves
the use of proteasome inhibitors. Proteasome inhibitors
have been shown to inhibit IBa degradation and pre-
vent NFB activation [27,28]. Since the activity of the
NFB canonical pathway relies on the proteasome
machinery, we sought to determine whether the use of
the proteasome inhibitor MG132 during immobiliza-
tion-induced stimulus would enhance physical
performance.
We recently showed that the inflammatory molecule
TNFa is involved in skeletal muscle atrophy using an
immobilized hindlimb mouse model [14]. TNFa is
known to increase the activity of the canonical NFB
pathway in conditions associated with muscle weakness,
including sepsis, cancer, and ageing [36-39] and to
cause protein degradation in cultured myotubes [5,6]. In
fact, the ubiquitin-proteasome pathway has been shown
to be of major importance in the catabolic signaling of
TNFa leading to the breakdown of muscle protein [40].
Ubiquitinated proteins are selectively targeted for degra-
dation through the 26S proteasome pathway by tissue-
specific E3 ligases [12,13] that catalyze the transfer of
activated ubiquitin. The muscle-specific E3 ligases
MuRF-1 and Atrogin/MAFbx are part of atrophy [13]. A
review of the literature revealed slight differences in the
results regarding the genes involved in the proteasome
degradation pathway when it is perturbed by an increase
in NFB activity. MuRF1 mRNA, but not Atrogin/
MAFbx mRNA, is upregulated in the gastrocnemius
muscle of transgenic mice with constitutive NFBa c t i v -
ity [8]. Judge et al. electrotransferred a dominant nega-
tive IBa into the soleus muscle of mice that were
subsequently tested in an unloading atrophy model.
They showed that Atrogin/MAFbx but not MuRF-1 is
regulated by the NFB pathway in the soleus muscle
[11]. On the other hand, Bodine et al. (2001) used dis-
use, denervation, and hindlimb suspension models of
atrophy to show that both MuRF1 and Atrogin/MAFbx
are upregulated in the gastrocnemius muscle [13]. These
slight differences may be due to the different types of
muscle studied, the backgrounds of the animals used,
and the different models used to induce muscle atrophy.
In the present work, we showed that the proteasome
inhibitor MG132 interfered with the NFB canonical
pathway of TNFa-treated C2C12 cells by protecting
IBa from degradation and thus preventing the activa-
tion of NFB transcription. Lastly, we showed that
MG132 prevents the TNFa-induced up-regulation of
MuRF1 and Atrogin-1/MAFbx in vitro. Our results
demonstrated that MG132 protects IBa from degrada-
tion, which confirmed the central role of the proteasome
machinery in the activation of the NFB canonical path-
way [41,42].
We used an immobilization model that induced skele-
tal muscle atrophy to show that a treatment with the
proteasome inhibitor MG132 prevented the immobiliza-
tion-induced atrophy of the TA muscle. These results
correlated with the histological analysis showing that
MG132 preserved myofiber size during immobilization.
The proteasome inhibitor Velcade™ (also known as PS-
341 or Bortezomib™) has been shown to partially but
significantly reduce the denervation-induced atrophy of
the soleus muscle [22]. The authors concluded that the
partial inhibition was due to an inadequate dose of Vel-
cade™ or other proteolytic mechanisms that are not
inhibited by the drug, such as the Ca
2+-dependent pro-
tease or lysosomal pathways, which are also known to
be involved in muscle wasting [43]. In addition to inhi-
biting proteasome activity, MG132 has been reported to
repress certain lysosomal cysteine proteases and calpains
[44], which might also explain the total rescue of muscle
mass in our study.
The immobilization-induced model is known to cause
an early inflammatory process characterized by the up-
regulation of TNFa, IL-1, and IL-6 mRNA, which are
targets of the canonical NFB pathway [45-47]. Interest-
ingly, treating mice with MG132 prevented the up-regu-
lation of these pro-inflammatory genes during
immobilization. Likewise, the levels of MuRF-1 and
Atrogin/MAFbx mRNA, which are targets of NFB,
increased after immobilization. This effect was pre-
vented by MG132, which completely inhibited the
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Page 8 of 11expression of MuRF-1 mRNA. Surprisingly, unlike the
in vitro experiment, MG132 did not completely inhibit
Atrogin/MAFbx mRNA expression in immobilized mice,
but did significantly attenuate it. We cannot rule out
the involvement of another mechanism in the increase
in Atrogin/MAFbx mRNA levels in vivo. There is some
evidence suggesting that disuse muscle atrophy induced
by unloading is associated with the activation of an
alternative NFB pathway distinct from the pathway
seen with cachexia where TNFa is responsible for mus-
cle atrophy [48,49]. Despite the fact that we observed an
up-regulation of the canonical NFB pathway target
genes for TNFa, IL-1, and IL-6 [45-47], it is possible
that there is a cross-over between with the non-canoni-
cal NFB pathway, which is independent of IBa. Other
investigators have shown that TNFa mediates the upre-
gulation of atrogin/MAFbx expression in the skeletal
muscle via p38MAPK [10,50]. These conflicting findings
suggest that multiple signaling pathways mediate muscle
wasting, and highlight the complexity of the molecular
pathways involved in the regulation of skeletal muscle
atrophy.
To correlate the morphological, histological, and
molecular results with the functional properties of TA
muscles from MG132-treated mice, we evaluated the
time to exhaustion performance of mice. Our results
showed that the endurance of MG132-treated mice was
significantly higher than that of vehicle-treated control
mice after 4 days of remobilization. However, no signifi-
cant differences were observed after 11 days of remobili-
zation. Indeed, after 11 days, the time to exhaustion was
similar to that of mice that had never had their hin-
dlimbs immobilized.
Conclusion
In summary, we showed that the proteasome inhibitor
MG132 is able to inhibit the activation the NFBp a t h -
w a yb yi n h i b i t i n gt h ed e g r a d a t i o no fI Ba in vitro. We
showed that MG132 prevent the up-regulation of
TNFa, IL-1 and IL-6 mRNA, which are target genes of
the canonical NFkB pathway in the TA muscle of hin-
dlimb immobilized mice. A direct consequence of the
MG132 treatment was the repression of MuRF-1 and
Atrogin/MAFbx, which may explain why the loss of
muscles mass and the decrease in myofiber CSA was
lower in the TA muscles of MG132-treated mice. To
our knowledge, this is the first study to clearly show
that preventing atrophy by inhibiting the proteasome
can shorten the rehabilitation period following immobi-
lization. In conclusion, we showed that proteasome inhi-
bitors protect muscle integrity and functionality. The
use of pharmacological agents directed against the pro-
teasome may be an avenue of great interest for develop-
ing therapies to prevent muscle atrophy and improve
the rehabilitation of patients following severe trauma or
surgery.
Additional material
Additionnal file 1: Cast immobilization induced inflammation and
the expression of muscle-specific ubiquitin ligase. (A) Photograph
showing a mouse hindlimb immobilized using a plaster cast. The
hindlimb is in the neutral position. (B) Histogram showing the
percentage of weight loss of TA after 7 days of immobilization as
compared to TA from non-immobilized hindlimbs (n = 4). (C) Graphs
showing RNA expression levels of the inflammatory markers TNFa, IL-6,
and IL-1. The levels of these markers were significantly higher at 24 h, 3.5
d, and 7d post-cast immobilization than in non-immobilized hindlimbs.
(C) Graphs showing the expression of MuRF1 and Atrogin-1 transcripts.
The levels of MuRF-1 and Atrogin-1 transcripts were significantly higher
at 24 h, 3.5 d, and 7 d post-immobilization than in non-immobilized
hindlimbs. n = 4/time studied (*p < 0.05, **p < 0.005, ***p < 0.001
compared to control).
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